Magnesium bisglycinate for sleep: 2025 trial results

For magnesium bisglycinate, the strongest new sleep claim is also a carefully bounded one. A 2025 randomized trial gives the supplement more support than the usual capsule-aisle promise, but it does not turn magnesium into an insomnia treatment.

Schuster and colleagues, writing in Nature and Science of Sleep, reported that 250 mg of elemental magnesium, delivered as magnesium bisglycinate for 4 weeks, modestly improved insomnia severity in adults who already described their sleep as poor. In the randomized placebo-controlled trial, the Insomnia Severity Index fell more with magnesium than with placebo. The gap was real enough to discuss, yet too small to justify a broad sleep claim.

For an evidence analyst, that is the useful tension. Testing a specific form, dose and outcome is much better than asking whether “magnesium” helps sleep in the abstract. A skeptic can read the same data another way: if the stronger signal appears in people with lower baseline magnesium status, the supplement may be correcting a shortfall in some participants, not treating sleeplessness as a category.

Here is why the distinction matters. Magnesium has become a catch-all wellness answer for restless nights. This bisglycinate trial suggests a narrower possibility: some adults with poor sleep may improve a little, especially if their magnesium intake or status is low. It does not show that everyone with insomnia should add a capsule before bed.

What the 2025 trial actually tested

Researchers enrolled 155 generally healthy adults aged 18-65 who reported poor sleep. Participants were randomly assigned to magnesium bisglycinate or placebo for 4 weeks. Their main outcome was the Insomnia Severity Index, a patient-reported questionnaire used to track perceived insomnia symptoms.

Each daily dose supplied 250 mg of elemental magnesium. That is not a blanket dosing recommendation. Anyone considering a magnesium supplement, especially people with kidney disease, those taking medications, pregnant people or anyone already using sleep drugs, should consult a doctor before starting any supplement.

By week 4, Insomnia Severity Index scores had fallen by 3.9 points in the magnesium group and 2.3 points in the placebo group, according to Schuster and colleagues. The raw difference is large enough to notice in a trial table. It is also modest. Sleep questionnaires often improve in placebo groups because study participation itself changes routines, attention and expectations.

Against most consumer sleep advice, the design was still stronger. Randomization, placebo control and a form-specific supplement all help. The paper did not ask participants whether they liked magnesium. It tested magnesium bisglycinate against an inactive comparator and measured change over time. In a supplement category crowded with broad claims, that counts as progress.

Several limits keep the finding small. The trial was short. It relied heavily on self-reported sleep rather than polysomnography or other objective lab sleep measures. It included adults with poor sleep, not necessarily people with clinically diagnosed insomnia. Those choices make the finding easier to apply to everyday supplement shoppers, but harder to treat as medical-grade insomnia evidence.

The subgroup signal is the most interesting part

Average effects may not be the most useful result. More revealing is the hint that people with lower magnesium status or intake may have gained more.

Basic physiology makes that plausible without proving a treatment rule. Magnesium is involved in neuromuscular function, cellular energy metabolism and nervous-system signaling. If a person is not getting enough, restoring sufficiency could affect restlessness or sleep quality. With adequate intake already in place, adding more may do little beyond raising supplement intake.

Mah and Pitre’s 2021 systematic review and meta-analysis of oral magnesium for insomnia in older adults points in the same cautious direction. It found small changes, including about 17 minutes less sleep onset latency and about 16 minutes more total sleep time, but the evidence base was limited and the certainty was low. In plain English: the signal was plausible, not settled.

By narrowing the question, the 2025 bisglycinate paper improves the conversation. “Does magnesium work?” is too broad. “Who, if anyone, responds to a particular form of magnesium?” is less catchy, but more honest.

A 2024 Cureus systematic review reached a similarly uneven conclusion for self-reported anxiety and sleep quality. Some studies showed benefit. Others were hard to interpret because they used different populations, formulas, doses and outcomes. That heterogeneity is not a footnote. It is the story.

Form matters, but not as much as marketers imply

Marketers often describe bisglycinate as a gentler or more absorbable magnesium form. That may be part of its appeal for sleep, since gastrointestinal side effects can make other magnesium salts unpleasant at higher intakes. Better tolerability, though, is not the same as proven sleep efficacy.

Form-specific evidence is also getting messier. Hausenblas and colleagues reported in a 2024 magnesium L-threonate randomized trial that adults with self-reported sleep problems improved on several subjective and wearable-derived outcomes over 21 days. That was not a bisglycinate study, and L-threonate is marketed partly around brain magnesium delivery rather than simple mineral repletion.

Read together, the bisglycinate and L-threonate trials do not prove that form-specific magnesium supplements solve sleep problems. They suggest the old generic claim is too crude. Different salts may have different tolerability, absorption profiles, marketing claims and study designs. Readers should be wary when a brand uses evidence from one form to sell another.

For brands, the cleanest rule is also the most restrictive one: match each claim to the evidence. A bisglycinate capsule can point to the 2025 trial only if the claim stays close to what the trial measured: adults with poor sleep, 250 mg elemental magnesium, 4 weeks, modest improvement in insomnia severity. Stronger language outruns the data.

What this means for someone considering magnesium

Readers should not translate this paper into “take magnesium for sleep.” A better starting point is a sequence of less glamorous questions. Is dietary magnesium intake low? Are there symptoms or medical reasons to suspect deficiency? Is the sleep problem new, severe, medication-related, hormonal, stress-driven or tied to sleep apnea? Has a clinician already ruled out causes that a supplement will not fix?

On that reading, the 2025 trial makes magnesium bisglycinate look reasonable as a possible adjunct for some adults with poor sleep. It does not make it a substitute for cognitive behavioral therapy for insomnia, treatment of sleep apnea, medication review or basic sleep scheduling when those are the real drivers.

Because the benefit appears small, expectations should stay modest. A person who takes magnesium and falls asleep 15 minutes faster may consider that worthwhile. Someone expecting a supplement to reverse chronic insomnia will likely be disappointed. Both reactions can be consistent with the same evidence.

Safety is another reason not to make blanket recommendations. Magnesium from food is generally safe for healthy adults, but supplemental magnesium can cause diarrhea, nausea and cramping. Higher supplemental intake can be risky in kidney disease because magnesium clearance may be impaired. People taking antibiotics, bisphosphonates, diuretics, heart medicines or other regular prescriptions should ask a clinician or pharmacist before adding magnesium.

The bottom line

Direct testing gives magnesium bisglycinate a better sleep evidence base than many magnesium products. That matters. It moves the conversation beyond vague mineral lore and into a measurable, if still early, clinical signal.

Still, the trial should lower the temperature, not raise it. Schuster and colleagues showed a modest improvement in self-reported insomnia severity over 4 weeks. Mah and Pitre’s older-adult meta-analysis and the broader 2024 review both suggest the wider magnesium literature remains mixed, small and population-dependent. Hausenblas and colleagues add another form-specific trial, but not a universal rule.

Conditionality is the most accurate answer. Magnesium bisglycinate may improve sleep for some adults, especially those with low magnesium intake or status, but the evidence does not support a blanket recommendation for insomnia. The next useful studies will need larger samples, longer follow-up, objective sleep measures and clearer subgroup testing.

For now, magnesium bisglycinate belongs in the “possibly helpful, not proven as a general treatment” bucket. That is less exciting than supplement marketing. It is also closer to what the evidence actually says.

References

1. Schuster J, Cycelskij I, et al. Magnesium bisglycinate supplementation in healthy adults reporting poor sleep: a randomized, placebo-controlled trial. Nature and Science of Sleep. 2025. DOI: 10.2147/NSS.S524348
2. Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2021. DOI: 10.1186/s12906-021-03297-z
3. Hausenblas HA, Lynch T, Hooper S, Roth T. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: a randomized controlled trial. Sleep Medicine: X. 2024. DOI: 10.1016/j.sleepx.2024.100121
4. Mahmud S, et al. Examining the effects of supplemental magnesium on self-reported anxiety and sleep quality: a systematic review. Cureus. 2024. Full text